Strategic capital doubles down on efficacy skincare: Where the next growth curve lies

Strategic capital doubles down on efficacy skincare has been gaining momentum. Data shows that in Q4, online channel share reached 55%, and industry attention is clearly rising. This piece breaks down where the next growth curve lies using public information and platform data.

Supply-side changes are equally visible. Dr.Alva’s layout in Southeast Asia, together with pricing from new entrants, is driving this round of adjustment — and concentration is moving with it.

Two signals stand out from Dr.Alva’s latest moves: resources keep concentrating at the top, while incremental markets like Southeast Asia gain bargaining power.

For practitioners, three directions follow: differentiate product and content back to R&D and supply chain; build localisation capability for markets such as Southeast Asia; and treat compliance and data capability as the new moat.

Bottom line: strategic capital doubles down on efficacy skincare is moving from concept to execution — where the next growth curve lies. Brands should review strategy before Q4 and prioritise channels and segments with higher certainty.

Related